Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bionomics inks pain agreement with Merck
September 2013
SHARING OPTIONS:

ADELAIDE, South Australia—An option and license agreement was struck at the end of July between Merck and Bionomics Ltd. for the discovery and development of novel small-molecule candidates for treating chronic pain, including neuropathic pain. Per the terms of the agreement, Merck will have an option to exclusively license a compound from Bionomics for development and commercialization, for which Bionomics will receive option exercise fees and development and regulatory milestone payments of up to $172 million. Bionomics may be eligible for royalties on net sales of products resulting from the collaboration as well, and will retain the development and commercialization rights to certain compounds for which Merck chooses not to exercise its option. The program is originally slated to run for two years, and will make use of Bionomics' ionX drug discovery platform and MultiCore chemistry.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.